

Quizartinib Therapy for FLT3-positive Acute Myeloid Leukaemia

Amna Faheem Mufti¹, Abdul Wahid Rizwan², Adeena Azam³

Madam, Globally, acute myeloid leukaemia (AML) is a common concern among leukaemia patients. It is the most common form of leukaemia in adults. Various genetic mutations are associated with AML. Around 30% of patients carry mutations in the FLT3 receptor, with LT3-ITD being the most common and associated with a poor prognosis.¹

Current treatment for this type of AML in Pakistan includes induction chemotherapy with Daunorubicin and Idarubicin, followed by allogeneic stem cell transplant or cytarabine.² Quizartinib is a new oral agent that selectively targets the FLT3-ITD mutation and has shown promising results in a newly conducted trial, the QuANTUM-First trial. The trial shows that adding Quizartinib to standard chemotherapy with or without allogeneic stem cell transplant, followed by monotherapy with the drug for up to 3 years, resulted in improved overall survival in adults aged 18–75 years with FLT3-ITD-positive newly diagnosed AML.³

Allama Iqbal Medical College, Lahore, Pakistan; ²King Edward Medical University, Lahore, Pakistan; ³Jinnah Hospital, Lahore, Pakistan.

Correspondence: Amna Faheem Mufti. e-mail: amna.mufti@yahoo.com

ORCID ID: 0009-0009-2459-4564

Submission complete: 03-03-2024

Review began: 17-04-2024

Acceptance: 01-08-2024

Review end: 17-04-2024

This information is crucial for physicians treating AML in Pakistan, as targeted therapeutic agents like Quizartinib must be studied and developed here. Trials should be conducted to reveal the efficacy and safety of these agents specific to the Pakistani population, as these could drastically improve the survival rate and overall prognosis of AML patients.

Disclaimer: None.

Conflict of Interest: None.

Funding Sources: None.

DOI: <https://doi.org/10.47391/JPMA.20166>

References

1. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. *Leukemia* 2019;33:299-312. doi: 10.1038/s41375-018-0357-9
2. Zulfiqar M, Ali N, Shaikh U, Jehanzeb H, Arif S, Khan ZF, et al. Outcomes of Patients with FLT3 Positive Acute Myeloid Leukaemia; an Experience from a Tertiary Care Hospital in Karachi, Pakistan. *J Cancer Allied Spec* 2023;9:553. doi: 10.37029/jcas.v9i2.553
3. Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Žák P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2023;401:1571-83. doi: 10.1016/S0140-6736(23)00464-6

Author Contribution:

AFM: Topic, wrote the first draft, final approval and agree to be accountable for all aspects of the work.

AWR: Searched the related articles, edited the first draft, final approval and agree to be accountable for all aspects of the work.

AA: References, completed the final editing, final approval and agree to be accountable for all aspects of the work.